Semaglutide
FDA-approved GLP-1 receptor agonist for weight management and blood sugar control
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally approved for type 2 diabetes that has demonstrated powerful weight loss results. It works by increasing insulin secretion, suppressing appetite through brain receptors, and slowing gastric emptying. When combined with a reduced-calorie diet and lifestyle changes, semaglutide produces significant, sustained weight loss. It is compounded with Pyridoxine (B6) to help reduce nausea.
- Weight management and obesity treatment
- Blood sugar control in type 2 diabetes
- Reduction of cardiovascular risk events
- Appetite suppression and reduced food cravings
- Lowering BMI and A1C levels
Dosage & Instructions
Form
Subcutaneous injection
Amount
As prescribed — typically starting low and titrating up
Frequency
Once weekly
Timing
Same day each week, any time of day
Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites. Follow your provider's titration schedule.
Dosage Schedule
| When | Dose | Notes |
|---|---|---|
| Weeks 1–4 | Starting dose as prescribed | Low starting dose to minimize GI side effects |
| Weeks 5–8 | Increased dose per provider plan | Titrate up as tolerated |
| Maintenance | Target maintenance dose | Continue weekly as directed by your provider |
Side Effects
Common
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
Less Common
- Fatigue
- Dizziness
- Abdominal discomfort
- Injection site reactions
Serious — Seek Care
- Pancreatitis — stop and contact provider if severe abdominal pain occurs
- Gallbladder problems
- Increased heart rate — notify provider
- Hypoglycemia when combined with other diabetes medications
Drug Interactions
- Insulin and other diabetes medications — risk of hypoglycemia
- Oral medications — semaglutide slows gastric emptying and may affect absorption timing
- Inform your provider of all medications and supplements